Why this matters: Three distinct signals converged on ENTX this week. The borrow market swung from near-zero availability to relative ease in days. Simultaneously, options traders made the sharpest shift toward calls seen all year.
The story starts in the lending pool. On September 17–18, availability on ENTX collapsed to 3.5–3.8% — one share still available for every 26 already borrowed. That is among the tightest borrow conditions the stock has recorded in a year.
Then the reversal came fast. By September 24, availability had rebounded to 60.8%. That is a 1,630% jump in one week. The pool loosened sharply, and short sellers moved quickly. Short interest jumped 49% in a single day, from roughly 892,000 shares to 1.33 million — a wave of new shorts entering as borrowing became practical again.
Cost to borrow remains elevated. It sits at 14.2%, up 30% over the past month. That level prices ENTX firmly in the hard-to-borrow tier, even after the availability recovery.
While the borrow market was whipsawing, the options market told a different story. The put-call ratio dropped to 1.07 on September 24. The 20-day average was 5.23. That is a z-score of –2.10 — the lowest PCR reading in 52 weeks.
For most of August and early September, ENTX options were overwhelmingly skewed toward puts. PCR readings of 6–9 were routine. The flip to ~1.07 represents an aggressive rotation into calls. Something changed in how options traders are positioning on this name.
The options shift arrives just days after two fresh initiations. Cantor Fitzgerald initiated coverage with an Overweight rating on September 22. Leerink Partners initiated Outperform with a $9.00 target on September 18. The consensus now sits at Buy, with a mean price target of $9.33 — more than three times the September 24 close of $2.80.
The bull case rests on EB613, Entera Bio's Phase 3 osteoporosis candidate, and FDA alignment on its primary endpoint. Bears point to competition from existing treatments and clinical-stage financial risk.
BVF Partners L.P. filed a Schedule 13D in August, disclosing a 9.99% activist stake — as last disclosed, per regulatory timing conventions. Several other institutions disclosed large new positions in the same August filing window. The register became notably more concentrated in a short period.
See the live data behind this article on ORTEX.
Open ENTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
